Product image of Ocplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F) supplied by GNH India

Ocplex

Active Ingredient:
Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F
Origin:
EU

Ocplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F)

Human Coagulation Factor IX (recombinant), the active ingredient in Ocplex, is a coagulation factor replacement therapy presented as a sterile solution for intravenous use. It treats hemophilia B by providing the missing clotting factor in affected individuals. GNH India supplies Ocplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH India supplies Ocplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Octapharma (Ip) Sprl

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ocplex is a recombinant coagulation factor used within the hemophilia B treatment pathway to replace deficient Factor IX.

  • Hemophilia B: Provides temporary correction of Factor IX deficiency to control and prevent bleeding episodes.
  • Peri‑operative management: Supplies necessary Factor IX levels for surgical procedures in patients with hemophilia B.
  • Trauma‑induced bleeding: Offers rapid factor replacement to manage acute bleeding in hemophilia B patients.

How It Works

  • Ocplex contains recombinant human Factor IX that binds to phospholipid surfaces at sites of vascular injury, forming part of the intrinsic tenase complex. This complex activates Factor X to Xa, leading to thrombin generation and fibrin clot formation, thereby restoring normal coagulation in patients lacking functional Factor IX.

Side Effects

Adverse reactions to recombinant Factor IX products are generally infrequent but can occur.

Common Side Effects

  • Injection site erythema: Redness at the infusion site.
  • Mild headache: Transient head discomfort.
  • Low‑grade fever: Slight increase in body temperature.
  • Transient nausea: Short‑lasting feeling of nausea.
  • Fatigue: Generalized tiredness.
  • Mild arthralgia: Minor joint discomfort.

Serious or Rare Side Effects

  • Anaphylaxis: Severe allergic reaction requiring immediate medical attention.
  • Development of inhibitors: Neutralizing antibodies that reduce drug efficacy.
  • Thromboembolic events: Blood clots forming in vessels.
  • Severe hypersensitivity: Rash, swelling, or respiratory distress.
  • Renal impairment: Deterioration of kidney function.
  • Hepatic dysfunction: Elevated liver enzymes or liver injury.

Precautions & Warnings

When using Ocplex, clinicians should observe several safety measures.

  • Dosing individualized: Adjust dose based on patient’s Factor IX activity levels and clinical response.
  • Monitor inhibitors: Regularly test for anti‑Factor IX antibodies that may affect efficacy.
  • Bleeding surveillance: Observe for signs of uncontrolled bleeding or bruising.
  • Concomitant anticoagulants: Use caution when patients are also receiving anticoagulant therapy.
  • Pregnancy and lactation: Evaluate risk‑benefit ratio before administration.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ocplex may interact with other agents that affect hemostasis.

Major Interactions (Avoid)

  • Direct oral anticoagulants (DOACs): May counteract the clotting effect of Factor IX.
  • Warfarin: Combined use can increase bleeding risk.
  • Antiplatelet agents (e.g., aspirin, clopidogrel): Heightened risk of hemorrhage.

Moderate Interactions (Monitor Closely)

  • Immunosuppressants: May influence inhibitor development.
  • Antibiotics such as vancomycin: Potential for altered immune response.
  • Intravenous immunoglobulin (IVIG): May affect pharmacokinetics of Factor IX.

Frequently Asked Questions

Ocplex is a recombinant human Factor IX product indicated to replace deficient clotting factor in patients with hemophilia B. It is used to control bleeding episodes, provide prophylactic coverage, and support surgical or traumatic situations where adequate hemostasis is required.

The recombinant Factor IX in Ocplex binds to phospholipid surfaces at vascular injury sites, forming part of the intrinsic tenase complex that activates Factor X. This cascade generates thrombin and fibrin, restoring normal clot formation in individuals lacking functional Factor IX.

Dosage is individualized by the prescribing clinician based on the patient’s Factor IX activity level, severity of bleeding, body weight, and clinical response. The prescriber determines the exact amount and frequency of administration.

Safety data are limited, so the risk‑benefit profile should be carefully evaluated by the treating physician. Use is generally considered when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

Submit an enquiry on the Ocplex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ocplex is a recombinant Factor IX product, offering a purified, virus‑inactivated protein similar to other recombinant Factor IX therapies. Compared with plasma‑derived products, it reduces the risk of pathogen transmission and provides consistent potency, though dosing frequency and inhibitor risk may differ among brands.

Ocplex should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

Ocplex is given by intravenous infusion, typically through a peripheral or central line. The infusion rate and volume are determined by the prescriber, and the product must be administered under aseptic conditions by a qualified healthcare professional.

The most serious risks include the development of neutralizing inhibitors that reduce efficacy, severe allergic reactions such as anaphylaxis, and rare thromboembolic events. Patients should be monitored closely for any signs of these reactions.

Ocplex is contraindicated in patients with known hypersensitivity to any component of the formulation, including the recombinant protein or excipients. It should also be avoided in individuals with a history of severe inhibitor development unless benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT